Full Text of PDF (485k)
Article in Japanese
Abstract
Case Report
EGFR exon 20 insertion mutations in lung adenocarcinoma with a remarkable response to pembrolizumab: a case report
Ryota Horibea Takeyuki Sawaib Kanami Sugaa Tatsuru Ishikawac Midori Hashimotoa Kaoru Nishiyamaa
aDepartment of Pulmonary Medicine, NTT Medical Center Sapporo
bDepartment of Pulmonary Medicine, Hakodate Goryokaku Hospital
cDepartment of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine
ABSTRACT
A 78-year-old woman was referred to our hospital because of a lung tumor. The diagnosis was lung adenocarcinoma (cT4N3M1a, Stage IVA) with EGFR mutations (exon 20 insertion) and high expression of PD-L1 (95%). She received pembrolizumab as the primary treatment, resulting in an immediate antitumor effect. While she received a total of 17 courses of treatment, a partial response was maintained. We report a rare case of adenocarcinoma harboring EGFR exon 20 insertion mutations that responded to treatment with an immune checkpoint inhibitor.
KEYWORDS
EGFR-mutant lung adenocarcinoma Exon 20 insertion mutation Immune checkpoint inhibitor (ICI)
Received 25 Dec 2019 ／ Accepted 17 Feb 2020
AJRS, 9(3): 191-195, 2020
Copyright © The Japanese Respiratory Society All Rights Reserved.